Page 96 - Genes News Today

University of Virginia School of Medicine researchers have created an "atlas of atherosclerosis" that reveals, at the level of individual cells, critical processes responsible for forming the harmful plaque buildup that causes heart attacks, strokes and coronary artery disease.

Do epigenetic changes cause type 2 diabetes, or do the changes occur only after a person has become ill? A new study by researchers at Lund University provides increased support for the idea that epigenetic changes can cause type 2 diabetes.

Researchers evaluated the effectiveness of adeno-associated virus (AAV)-mediated Plakophilin 2 (PKP2) delivery in treating arrhythmogenic cardiomyopathy (ACM).

While lifestyle habits are a large part in the development of obesity, researchers are finding there may be more to the story.

Human fingers and toes do not grow outward; instead, they form from within a larger foundational bud, as intervening cells recede to reveal the digits beneath. This is among many processes captured for the first time as scientists unveil a spatial cell atlas of the entire developing human limb, resolved in space and time.

Study demonstrates that inhibiting stromal class I histone deacetylases (HDACs) can effectively slow down pancreatic cancer progression, shedding light on a new therapeutic approach targeting the tumor microenvironment.

Scientists have created the first extensive map showing how all possible genetic changes can affect health in the gene DDX3X, leading to valuable insights into the underlying mechanisms of neurodevelopmental disorders and cancer.

Learn these facts about your genes. | Thehealthsite.com

Vertex and CRISPR Therapeutics have announced FDA approval for CASGEVY in treating sickle cell disease. Utilizing cutting edge CRISPR/Cas9 gene editing technology, a patient’s own genes are extracted, edited, and then reinserted to eliminate sickle cell in this new therapy.

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.